Hydroquinone two-year dermal toxicity mouse study suggested at OTC "feedback" meeting.
This article was originally published in The Tan Sheet
Executive Summary
HYDROQUINONE TWO-YEAR DERMAL TOXICITY MOUSE STUDY SUGGESTED by FDA Division of OTC Drug Products Medical Officer Arther Baker, MD, at a Dec. 4 OTC "feedback" meeting on the ingredient between the agency, the Nonprescription Drug Manufacturers Association, Eastman Kodak and other industry members. Baker recommended that industry conduct a "two-year dermal toxicity exposure at a maximum tolerated dose, which is probably about 5%" hydroquinone in a specific mouse strain.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning